IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"Shelf Life Evaluation Of Pharmaceuticals: A Study On Degradation Pathways"

[1]Akanksha Pokharkar, [2]Pooja Kasurde, [3]Vaishnavi Singh, [4]Megha V. Hange, [5]Dr. P.N. Sabale

[1]Student (M. Pharmacy), [2]Student (M. Pharmacy), [3]Student (M. Pharmacy), [4]Guide, [5]Principal

[1]Pharmaceutical Quality Assuranace,

[1]S.S.P. Shikshan Sansthan's Siddhi College of Pharmacy, Chikhali, Pune, India

Abstract: Shelf life determination of pharmaceutical products is a critical process in ensuring drug safety, efficacy, and quality over time. It involves evaluating how a drug product degrades under various environmental conditions and estimating the period during which it remains within acceptable specifications. Stability studies, guided by ICH Q1A (R2) guidelines, are essential in this process and form a key part of regulatory submissions. These studies include real-time and accelerated stability testing, retained sample testing, and cyclic temperature stress testing. Factors like pH and temperature significantly influence the rate of degradation, often illustrated using pH-rate profiles. Forced degradation studies, involving hydrolytic, oxidative, photolytic, and thermal stress, help validate the robustness of stability-indicating analytical methods. Techniques such as HPLC-UV, LC-MS/MS, HPTLC, and others are commonly employed for stability analysis. For estimating shelf life, methods including the FDA-recommended approach, direct and inverse methods, simulation techniques, and the Garrett and Carper model are applied. Together, these methodologies provide a scientific foundation for determining the shelf life of pharmaceutical products, supporting drug development, formulation optimization, and patient safety.

Keywords: Self Life Evaluation, Stability Testing, Forced Degradation Testing, PH Rate profile, Solution Kinetics.

I. INTRODUCTION

Determination of shelf life of pharmaceutical products is a complex yet essential process that involves considerable time, cost, and scientific expertise. It plays a critical role in ensuring the quality, efficacy, and safety of drug formulations throughout their shelf life. The scientific and commercial success of a pharmaceutical product largely depends on a thorough understanding of the drug development process and the numerous tasks and milestones necessary for a comprehensive development plan. Among these, pharmaceutical analysis and stability studies are among the most vital. They are used to confirm the identity, potency, and purity of both the active ingredients and the final formulation (Singh et al., 2000).

The stability of a pharmaceutical product is defined as its capability, when stored in a specified container/closure system, to maintain its physical, chemical, microbiological, therapeutic, and toxicological properties throughout its shelf life (Kommanaboyina et al., 1999). In simple terms, it is the extent to which a product retains the same characteristics and effectiveness it had at the time of packaging, within defined limits, throughout its storage and use period.

Stability testing assesses how environmental factors such as temperature, humidity, light, and oxygen impact the quality of a drug substance or finished product. The results are used to determine appropriate storage conditions, establish the product's shelf life, and recommend labeling instructions. Furthermore, stability data is a regulatory requirement for the approval of new drugs and formulations (Singh et al., 2000).

The complexity of stability testing stems from the wide variety of influencing factors. These include the inherent stability of the active pharmaceutical ingredient (API), interactions between the API and excipients, the manufacturing process, dosage form, container-closure system, and conditions encountered during transportation, storage, and handling. Chemical degradation mechanisms such as oxidation, reduction, hydrolysis, and racemization can significantly alter the stability profile of a product. These reactions may depend on pH, light exposure, temperature, radiation, and presence of catalysts, as well as the nature of the raw materials and the time elapsed since manufacturing.

Physical changes in pharmaceutical products—such as alterations in appearance, consistency, uniformity, clarity, moisture content, particle size and shape, pH, and packaging integrity—can also affect stability. These may result from mechanical stress like vibration, impact, abrasion, or exposure to extreme temperatures such as freezing and thawing.

Moreover, chemical degradation can lead to the formation of undesired by-products, reduced potency of the API, or loss of activity in excipients such as preservatives or antioxidants (Carstensen et al., 2000). Microbiological changes, including microbial contamination and reduced preservative efficacy, can further compromise product safety (Matthews et al., 1999).

Thus, a comprehensive stability testing strategy is not only a regulatory requirement but a scientific necessity for ensuring the shelf life and overall integrity of pharmaceutical products

Table 1: ICH Guidelines for Stability Testing

ICH Code	Guideline Title
Q1A	Stability Testing of New Drug Substances and Products (Second Revision)
Q1B	Stability Testing: Photostability Testing of New Drug Substances and Products
Q1C	Stability Testing of New Dosage Forms
Q1D	Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Products
Q1E	Evaluation of Stability Data
Q1F	Stability Data Package for Registration Applications in Climatic Zones III and IV
Q5C	Stability Testing of Biotechnological/Biological Products

Table 2: ICH Q1A Summary of Stability Parameters

Study Type & Condition	Storage Conditions	Period (Months)	Comments
General Case	25°C±2°C/60% RH±5% RH or 30°C±2°C/65% RH±5% RH	12	Must cover retest/shelf-life; includes storage, shipment, and usage
Intermediate	30°C±2°C/65% RH±5% RH	6	
Accelerated	40°C±2°C/75% RH±5% RH	6	
Refrigeration - Long Term	5°C±3°C	12	Must cover retest/shelf-life; includes storage, shipment, and usage
Refrigeration – Accelerated	25°C±2°C/60% RH±5% RH	6	
Freezer - Long Term	-20°C±5°C	12	Must cover shelf-life; includes storage, shipment, and usage

Table 3: CPMP Guidelines for Stability Testing

CPMP Code	Guideline Title
CPMP/QWP/576/96 Rev.1	Guideline on Stability Testing for Applications for Variations to a Marketing Authorization
CPMP/QWP/6142/03	Guideline on Stability Testing for Active Substances in Climatic Zones III and IV (EU Market)
CPMP/QWP/609/96 Rev.1	Declaration of Storage Conditions for Medicinal Products and Active Substances
CPMP/QWP/122/02 Rev.1	Stability Testing of Existing Active Substances and Finished Products
CPMP/QWP/072/96	Start of Shelf Life of the Finished Dosage Form
CPMP/QWP/2934/99	In-Use Stability Testing of Human Medicinal Products
CPMP/QWP/576/96	Stability Testing for a Type 2 Variation to a Marketing Authorization
CPMP/QWP/159/96	Maximum Shelf-Life for Medicinal Products

Microbiological Stability Studies

Microbiological stability plays a critical role in determining the shelf life of pharmaceutical products. Microorganisms can contaminate not only moisture-containing formulations such as creams, syrups, and suspensions but also solid dosage forms, particularly those containing natural polymers. These natural polymers often serve as nutrient sources for microbial growth, thereby compromising product safety and stability over time. Ensuring microbiological integrity is essential to prevent degradation, maintain therapeutic efficacy, and extend the product's usable shelf life.

II. TECHNIQUES FOR SHELF LIFE DETERMINATION

Types of Stability Testing

Stability testing is an essential process used throughout drug development to ensure that pharmaceutical products maintain their intended quality, safety, and effectiveness over time. This testing is carried out at various stages—from early development to product release—and under different environmental conditions. Depending on the purpose and methodology, stability testing can be classified into four main types.

i. Real-Time Stability Testing

Real-time stability testing involves storing the drug or product under the recommended storage conditions for an extended period to observe whether it remains stable over time. The goal is to measure actual degradation and determine the true shelf life of the product. This method is carried out over a duration that is long enough to detect any measurable degradation, while also ensuring that any changes observed are due to instability and not due to variations in the testing method. Samples are analyzed at regular intervals so that trends in stability can be clearly identified. Often, a batch with known stability properties is used as a reference to improve the accuracy of results. This also involves ensuring that instruments and reagents used during the testing remain consistent and reliable, with regular checks for any performance drift or discontinuity over time.

ii. Accelerated Stability Testing

Accelerated stability testing is done by exposing the drug or product to elevated stress conditions such as high temperature, humidity, light, or changes in pH. The idea is to speed up the degradation process so that one can predict the shelf life of the product without having to wait for months or years. This method helps in comparing different formulations and in estimating how long a product will remain stable under normal storage conditions. In this type of testing, samples are first subjected to stress, then stored in refrigerated conditions, and finally tested to measure the level of degradation. Because the entire process is completed in a shorter time, the chances of errors due to instability in the testing system are lower than in real-time studies.

The results from accelerated testing are typically compared with unstressed samples within the same assay, and the outcome is expressed as the percentage of recovery. To improve accuracy, it is recommended to conduct testing at four different high temperatures. However, for heat-sensitive substances such as proteins, care must be taken to avoid extreme temperatures that could cause denaturation. The basis of accelerated stability testing is the **Arrhenius equation**, which describes how the rate of chemical degradation increases with temperature:

$$K = A \cdot e^{\frac{-\Delta E}{RT}}$$

Where:
K = degradation rate constant
A = frequency factor (related to how often molecules collide)
ΔE = activation energy (kJ/mol)
R = universal gas constant (0.00831 kJ/mol·K)
T = absolute temperature (in Kelvin)

This equation allows scientists to predict how fast a drug will degrade at lower temperatures based on data collected at higher temperatures. When the activation energy of the degradation reaction is known, one can estimate the product's shelf life even without long-term testing.

iii. Retained Sample Stability Testing

Retained sample stability testing is a routine practice where samples from each manufactured batch (or at least a selected number of batches) are stored and tested periodically to monitor product stability during its market life. When a product is first introduced, samples from all batches may be stored. Later, only a small percentage of marketed batches (usually 2% to 5%) are selected for this purpose. These samples are tested at regular time intervals such as 3, 6, 9, 12, 18, 24, 36, 48, and 60 months, depending on the product's shelf life. This approach is called the **constant interval method**, where stability is checked at fixed periods to track any gradual degradation. A variation of this method includes testing samples already available in the market (market-sample testing), which reflects more realistic conditions, since the products are exposed to the real-world supply chain and storage environments.

iv.Cyclic Temperature Stress Testing

Cyclic temperature stress testing is not commonly used as a routine test for marketed pharmaceutical products. However, it is a useful tool in gaining deeper understanding of how a product may behave under real-world storage conditions. This type of testing is designed to simulate the daily temperature fluctuations that occur in the marketplace, such as during transport, warehousing, or storage in varying climates.

Since the Earth follows a 24-hour day-night cycle, the testing is usually structured around a 24-hour temperature cycle. The temperature range used for the cycles is selected based on the specific product and considers factors such as the recommended storage conditions and the product's known physical and chemical stability characteristics. Typically, the test alternates between a low and high temperature over a 24-hour period to mimic environmental variations. For meaningful results, around 20 such cycles are generally recommended.

This test helps to evaluate how well a product can tolerate repeated temperature changes, which may occur in real distribution scenarios. The results can be especially useful in assessing packaging adequacy, identifying degradation trends, and determining if special storage or shipping precautions are necessary.

v. Photostability Testing

Photostability testing is performed to evaluate how exposure to light affects the stability of a drug substance or product. In 1996, the U.S. FDA adopted the ICH guidelines stating that the light sensitivity of new drugs must be assessed to ensure that light exposure does not lead to unacceptable changes in the product's quality. This type of testing is typically carried out on a single batch of the drug. However, if changes are made to the formulation, manufacturing process, or packaging, the test should be repeated to ensure consistent stability under light exposure.

The standard light source used in these tests is known as **D65**, which represents average outdoor daylight conditions, as defined by ISO 10977 (1993). For indoor lighting conditions, **ID65** is used, which simulates indirect daylight exposure. Photostability chambers are commonly used for these tests and have become standard practice, particularly for products intended for markets in Asia, where environmental conditions may vary widely. The purpose of this testing is to ensure that the product remains safe and effective throughout its shelf life, even when exposed to normal lighting conditions during manufacturing, storage, or use.

III. Forced Degradation Testing

Forced degradation testing, also known as stress testing, is a laboratory procedure in which drug substances or products are exposed to extreme environmental conditions to accelerate the chemical breakdown process. This approach is used to intentionally generate degradation products in a shorter period—usually within a few weeks—compared to standard stability testing. The purpose of forced degradation is to understand the molecule's intrinsic stability, identify possible degradation pathways, and detect the types of degradation products that may form over time. These studies help in developing and validating **stability-indicating analytical methods**, which can accurately detect changes in the drug's quality. Although forced degradation is not officially part of the formal stability study requirements, it is a key scientific and regulatory tool used during drug development. Conditions applied during forced degradation typically include high temperature, strong acidic or basic environments, oxidation, and exposure to light or moisture.

IV. pH-Rate Profiles

A pH-rate profile represents how the degradation rate of a drug changes with pH. It is typically displayed as a plot of the logarithm of the degradation rate constant (log *k*) versus pH. This profile, also known as a **pH-stability profile** or **rate–pH profile**, helps scientists understand the stability behavior of drug molecules in solution. It is especially useful in the design of stable liquid or lyophilized formulations and provides insight into whether acid or base catalysis plays a role in the degradation process.

Most drug degradation reactions follow **apparent first-order kinetics**. In such cases, the rate of degradation may be influenced by both specific and general acid-base catalysis. To accurately analyze the catalytic effect of buffers, corrections are made by extrapolating data to zero buffer concentration. The general rate expression can include contributions from hydrogen ions, hydroxide ions, and buffer species:

$$k_{obs} = k_0 + k_H[H^+] + k_{OH}[OH^-] + k_{buffer1}[Buffer_1] + \dots \quad (3)$$

Depending on the degradation mechanism, different shapes of pH-rate profiles can be observed:

i. V-shaped and U-shaped Profiles

These profiles often occur in the degradation of carboxylic acid derivatives such as esters and amides. The pseudo-first-order rate constant in such cases is given by:

$$k_{obs} = k_0 + k_H[H^+] + k_{OH}[OH^-] \quad (4)$$

In these plots, the acidic region has a slope of -1, and the basic region has a slope of +1, indicating specific acid and base catalysis, respectively.



Fig. 1. pH-rate profiles for reactions consisting only a single reactive species with specific acid- base-catalysis

ii. Sigmoidal Profiles

Sigmoidal pH-rate profiles are typically observed when degradation involves ionizable species such as weak acids or bases. Around the **pKa** value of the molecule, both the ionized and unionized forms may degrade at different rates. The observed rate constant becomes a combination of the contributions from both species:

$$k_{obs} = \frac{k_1[HA] + k_2[A^-]}{[HA] + [A^-]} = k_1 \cdot \frac{[HA]}{C} + k_2 \cdot \frac{[A^-]}{C} \qquad (7)$$

Where C is the total drug concentration. A sigmoidal profile results when the pKa lies within the pH range being studied.



Fig. 2. Sigmoidal pH-rate profile

iii. Bell-Shaped Profiles

Bell-shaped profiles occur when a drug has two ionizable groups. The formation of a central species (often a zwitterion or monoprotic intermediate) that degrades slower than either the acidic or basic forms results in a maximum or minimum in the degradation rate. Such behavior may also result from a shift in the rate-determining step during the reaction (e.g., from A → B to B → C in a multistep pathway).



Fig. 3. Bell-shaped pH-rate profile

iv. Complex pH-Rate Profiles

More complicated profiles arise when multiple ionizable centers exist in the molecule, particularly when their pKa values are close. For instance, aspirin exhibits specific acid catalysis at low pH (<2), base catalysis at high pH (>10), and sigmoidal behavior in the intermediate pH range due to intramolecular catalysis.

v. Effect of Temperature

The temperature dependence of degradation rates can be analyzed using the Arrhenius equation:

$$k = A \cdot e^{\frac{-E_a}{RT}}$$

Where:

- k is the rate constant,
- A is the pre-exponential factor,
- E_a is the activation energy,
- R is the gas constant,
- T is the absolute temperature (K).

By plotting ln k versus $1/T$, one can calculate the activation energy (E_a), enthalpy ($\Delta H\neq$), and entropy ($\Delta S\neq$) of activation. Reactions catalyzed by hydrogen ions often show a positive $\Delta S\neq$, indicating an increase in disorder due to protonation, while spontaneous hydrolysis usually shows a negative entropy change, reflecting the ordered nature of bimolecular mechanisms.

V. SOLUTION KINETICS

The chemical degradation of pharmaceutical compounds in solution follows the fundamental principles of chemical kinetics. These principles describe how the concentration of a drug changes over time due to chemical reactions, such as hydrolysis, oxidation, or photolysis. In pharmaceutical systems, degradation typically occurs in aqueous solutions and can often be modeled using zero-order, first-order, or pseudo-first-order kinetics, depending on the reaction mechanism and the concentration of the reactants.

Understanding solution kinetics is critical during drug development, as it helps in predicting the stability and shelf life of a product. By studying the rate at which a drug degrades in solution, scientists can design more stable formulations, select appropriate pH ranges and excipients, and determine optimal storage conditions. These studies are also essential for developing reliable expiration dates and ensuring that the drug maintains its efficacy and safety throughout its intended use.

IV. RESULTS AND DISCUSSION

A review of current literature and guidelines shows that stability studies play a critical role in ensuring the quality and safety of pharmaceutical products. **Real-time and accelerated stability testing** are essential to estimate shelf life and identify degradation trends under controlled conditions. Accelerated testing, supported by the Arrhenius equation, allows quicker prediction of long-term stability based on temperature-dependent degradation rates.

Forced degradation testing has become an important tool in early drug development. It helps identify potential degradation products and is widely used to develop and validate **stability-indicating analytical methods**. Though not a formal ICH requirement, it supports regulatory submissions and ensures better control over product quality.

Photostability studies, as per ICH Q1B, highlight the importance of protecting light-sensitive drugs from degradation. Testing under standard D65 light conditions ensures proper packaging and storage recommendations, particularly for drugs prone to photodegradation.

pH-rate profiles provide valuable insights into the stability of compounds across different pH levels. Many drugs show V-shaped or sigmoidal degradation profiles, indicating specific acid or base catalysis. Understanding these profiles is essential for choosing appropriate formulation pH and buffer systems.

Overall, combining stress testing, kinetic modeling, and environmental sensitivity analysis provides a strong foundation for designing stable pharmaceutical products and meeting regulatory expectations.

VI. ACKNOWLEDGMENT

We would like to express our sincere gratitude to the faculty and staff of S.S.P Shikshan Sansthan's Siddhi College of Pharmacy for their continuous support and guidance during the preparation of this review article. Special thanks to the Department of Pharmaceutical Quality Assurance for providing access to literature and resources necessary for this work.

REFERENCES

[1] An Overview: Stability Study of Pharmaceutical Products And Shelf Life Prediction, ISSN 2349-8870 Volume: 2 Issue: 6 30- 40 Year: 2015

[2] An Approach to Drug Stability Studies and Shelf-life Determination, 19(1): 1-20, 2019; Article no.ACRI.52101 ISSN: 2454- 7077

[3] Stability Testing of Pharmaceutical Products, Journal of Applied Pharmaceutical Science 02 (03); 2012: 129-138, ISSN: 2231- 3354.

[4] Development of forced degradation and stability indicating studies of drugs—A review, 2095-1779 & 2013 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. http://dx.doi.org/10.1016/j.jpha.2013.09.003

[5] Pokharana M, Vaishnav R, Goyal A, Shrivastava A. Stability testing guidelines of pharmaceutical products. Jr of Drug Del & Therap. 2018;8(2):169-175.

[6] Rao G, Goyal A. Development of stability indicating studies for pharmaceutical products: An innovative step. Int. Jr. Pharm Chem & Anal. 2016;3(3):110-116.

[7] Panda A, Kulkarni S, Tiwari R. Stability studies: An integral part of drug development process. Int Jr of Pharm Res and Bio-Sci. 2013;2(6):69-80.

[8] Hildegard B. How to approach a forced degradation study. Life Science, Technical Bulletin Issue N31, SGS Life Science Services, Berlin, Germany. 2011;1-4.

[9] Jorgensen WJ, Laird ER, Gushurst AJ, Fleischer JM, Gothe SA, Helson HE, et al. Pure and Applied Chemistry. 1990;62: 1921–1932.

[10] Singh S, Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. PharmaTech On-Line; 2000.
(Accessed 21 August 2019)

[11] Handbook of modern pharmaceutical analysis, Volume III, page: 445-483 A Satinder and S Stephen.

[12] Lachman L., DeLuca P. Kinetic principles and stability testing. The theory and practice of industrial pharmacy, 2nd ed.
Philadelphia. Lea and Febiger, 1976; 32-89.

[13] Bott RF., Oliveira WP. Storage conditions for stability testing of pharmaceuticals in hot and humid regions. Drug Dev.and
Indus. Pharm, 2007; 33: 393 401.

[14] World Health Organization: Stability Testing Of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products;
WHO Technical Report Series, 2009; 953: 87-123.

[15] Mallu UR, Nair AK, Bandaru S, Sankaraiah J. Hold time stability studies in pharmaceutical industry: Review. Pharm Reg Aff.
2012;1(4):1-8.

[16] Shao J, Chow SC. Drug shelf-life estimation. Stat Sin. 2001;1:737-745.

[17] Carstensen JT. Drug Stability, Principles and Practices, Marcel Dekker, New York (2000)

[18] Capen R, Christopher D, Forenzo F, Ireland C, Liu O, Lyapustina S, et al. On the shelf life of pharmaceutical products. AAPS
PharmSciTech. 2012;13(3):911–8.

[19] Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Available guidance and best practices for
conducting forced degradation studies pharmaceutical technology; 2002.

[20] Bott RF, Oliveira WP. Storage conditions for stability testing of pharmaceuticals in hot and humid regions. Drug Dev Ind
Pharm. 2007;33:393-401.